161 related articles for article (PubMed ID: 9694916)
1. Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.
Ohlstein EH; Nambi P; Hay DW; Gellai M; Brooks DP; Luengo J; Xiang JN; Elliott JD
J Pharmacol Exp Ther; 1998 Aug; 286(2):650-6. PubMed ID: 9694916
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
Ohlstein EH; Nambi P; Lago A; Hay DW; Beck G; Fong KL; Eddy EP; Smith P; Ellens H; Elliott JD
J Pharmacol Exp Ther; 1996 Feb; 276(2):609-15. PubMed ID: 8632328
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
[TBL] [Abstract][Full Text] [Related]
4. Nonpeptide endothelin receptor antagonists. VII: Binding characteristics of [3H]SB 209670, a novel nonpeptide antagonist of endothelin receptors.
Nambi P; Pullen M; Wu HL; Lee D; Saunders D; Heys R; Aiyar N; Leber J; Elliott J; Brooks D; Ohlstein E; Ruffolo R
J Pharmacol Exp Ther; 1996 Jun; 277(3):1567-71. PubMed ID: 8667224
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist.
Hoshino T; Yamauchi R; Kikkawa K; Yabana H; Murata S
J Pharmacol Exp Ther; 1998 Aug; 286(2):643-9. PubMed ID: 9694915
[TBL] [Abstract][Full Text] [Related]
6. Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670.
Ohlstein EH; Beck GR; Douglas SA; Nambi P; Lago MA; Gleason JG; Ruffolo RR; Feuerstein G; Elliott JD
J Pharmacol Exp Ther; 1994 Nov; 271(2):762-8. PubMed ID: 7965794
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of a novel series of orally active nonpeptide ETA and ETA/B endothelin receptor-selective antagonists.
Doherty AM; Patt WC; Repine J; Edmunds JJ; Berryman KA; Reisdorph BR; Walker DM; Haleen SJ; Keiser JA; Flynn MA
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S358-61. PubMed ID: 8587414
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of two novel mixed ETA/ETB receptor antagonists, BQ-928 and 238, in the carotid and pulmonary arteries and the perfused kidney of the rabbit.
Maurice MC; Gratton JP; D'Orléans-Juste P
Br J Pharmacol; 1997 Jan; 120(2):319-25. PubMed ID: 9117126
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of PD 156707, an orally active ETA receptor antagonist.
Reynolds EE; Keiser JA; Haleen SJ; Walker DM; Olszewski B; Schroeder RL; Taylor DG; Hwang O; Welch KM; Flynn MA
J Pharmacol Exp Ther; 1995 Jun; 273(3):1410-7. PubMed ID: 7791115
[TBL] [Abstract][Full Text] [Related]
10. Agonist-dependent inhibition by peptide and nonpeptide endothelin receptor antagonists in the rabbit isolated pulmonary artery.
Beck GR; Douglas SA; Elliott JD; Ohlstein EH
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S385-8. PubMed ID: 8587422
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
Clozel M; Breu V; Gray GA; Kalina B; Löffler BM; Burri K; Cassal JM; Hirth G; Müller M; Neidhart W
J Pharmacol Exp Ther; 1994 Jul; 270(1):228-35. PubMed ID: 8035319
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.
Opgenorth TJ; Adler AL; Calzadilla SV; Chiou WJ; Dayton BD; Dixon DB; Gehrke LJ; Hernandez L; Magnuson SR; Marsh KC; Novosad EI; Von Geldern TW; Wessale JL; Winn M; Wu-Wong JR
J Pharmacol Exp Ther; 1996 Feb; 276(2):473-81. PubMed ID: 8632312
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic characterization of the novel, orally available endothelin-A--selective antagonist SB 247083.
Douglas SA; Nambi P; Gellai M; Luengo JI; Xiang JN; Brooks DP; Ruffolo RR; Elliott JD; Ohlstein EH
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S273-6. PubMed ID: 9595458
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the contractile effects and binding kinetics of endothelin-1 and sarafotoxin S6b in rat isolated renal artery.
Devadason PS; Henry PJ
Br J Pharmacol; 1997 May; 121(2):253-63. PubMed ID: 9154335
[TBL] [Abstract][Full Text] [Related]
15. Functional and binding characterization of endothelin receptors in human bronchus: evidence for a novel endothelin B receptor subtype?
Hay DW; Luttmann MA; Pullen MA; Nambi P
J Pharmacol Exp Ther; 1998 Feb; 284(2):669-77. PubMed ID: 9454813
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a potent and selective endothelin-B receptor antagonist, IRL 2500.
Balwierczak JL; Bruseo CW; DelGrande D; Jeng AY; Savage P; Shetty SS
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S393-6. PubMed ID: 8587424
[TBL] [Abstract][Full Text] [Related]
18. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
[TBL] [Abstract][Full Text] [Related]
19. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm.
Roux S; Breu V; Giller T; Neidhart W; Ramuz H; Coassolo P; Clozel JP; Clozel M
J Pharmacol Exp Ther; 1997 Dec; 283(3):1110-8. PubMed ID: 9399983
[TBL] [Abstract][Full Text] [Related]
20. Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperazin-1-yl) carbonyl]-L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl) glycyl-L-leucyl-D-tryptophyl]disodium salt], in human endothelinA and endothelinB receptors.
Masuda Y; Sugo T; Kikuchi T; Kawata A; Satoh M; Fujisawa Y; Itoh Y; Wakimasu M; Ohtaki T
J Pharmacol Exp Ther; 1996 Nov; 279(2):675-85. PubMed ID: 8930171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
